Oxaliplatinum medec

Oxaliplatinum medak is a platinum-containing drug used for oncological diseases. Oxaliplatin was first discovered almost forty years ago by Japanese scientists, and from 1919 to 1970 it was used as an advanced chemotherapeutic agent in an irreconcilable struggle against cancer of the rectum and large intestine. Oxoliplatin medak contains compounds of platinum with oxalate and complexon. The complexion in this compound is 1,2-diaminocyclohexane. Oxaliplatin medak has in its composition lactose monohydrate, which helps the action of the main component. This mixture is a dirty white mass, similar to last year's snow.

[1],

Indications Oxaliplatinum medec

Oxaliplatin medak is used as a chemical agent for inoperable oncological diseases of the gastrointestinal tract, malignant intestinal lesions, or after surgical removal of the original tumor, almost always simultaneously with 5-fluoroacyl and water-soluble vitamin B ₉. Also indications for Oxaliplatinum medak include the fight against diseases such as the cytoxicantum of disseminated colorectal cancer, which is characterized by the presence of a number of separate, yet uncombined, affected areas. Oxaliplatin medak is used by a chemotherapeutic agent in antitumor chemotherapy.

[2],

Release form

Oxaliplatin medak is available in the form of lyophilate in small transparent glass bottles weighing 50, 100, and 150 mg.

Lyofizate preparation Oxaliplatin medak-powder is more often white. Lactose monohydrate clarifies the platinum component of the oncoprotein. Oxaliplatinum medak is used for the infusion composition, which is prepared from the lyophilized drug. As lysophosphate monohydrate, lactose monohydrate is used as a substance to help preserve the lyophysate of Oxaliplatin medec without loss of structural integrity and biological activity.

[3]

Pharmacodynamics

Oxaliplatin medak is an oncological drug used as a cytostatic in which platinum atoms form a stable compound with dianion and 1,2 diaminohexane. Joint use with 5-ftoratsilom and vitamin B9 increase the cytotoxicity of the drug Oxaliplatinum medak. Water-sodium solutions of Oxaliplatinum medak disrupt the cellular metabolism, inhibit the synthesis of deoxyribonucleic acid. Exposure of the metabolic poison oxaliplatin medaka leads to the destruction of tumor cells and, as a consequence, to the antitumor effect.

[4], [5]

Pharmacokinetics

The high rate of metabolism of the drug Oxoliplatin medak leads to the fact that at the end of the injection, which lasts from 2 to 6 hours (depending on the patient's well-being) at a dose of 135 mg / m2, it is no longer definable, eighty-five percent of the drug is distributed in tissues and only Fifteen percent of the injected cytotoxic is present in the blood. Pt binds blood proteins, forming new albumin bridges. Oxoliplatinum medak is intensively removed from the body with urine in the first two days. In the first hundred hours with urine, 54% of the drug is excreted, a very small fraction of the cytoxidant is excreted with feces. With renal failure, the rate of cytostatic excretion of oxoliplatinum medaka from the body is significantly reduced, which leads to an increase in the number and strength of unwanted adverse reactions. With very poor kidney function, the withdrawal of the cytostatic of the active substance is extremely difficult and the attending physician should review the norms and doses of the drug.

[6], [7]

Dosing and administration

Oxaliplatin medak is administered by infusion. Infusion lasts 6-8 hours. The drug is prohibited for children. The infusion solution is prepared immediately before use. When combined with 5-fluorouracil, an infusion of the cytotoxic Oxaliplatin medaka should be administered first. Auxiliary therapy after surgical removal of primary neoplasm of colorectal cancer is carried out at 85 mg / m ² once in 14 days (12 cycles). With dissiminated colorectal cancer, the same doses are used as with adjuvant therapy with fluorouracil. The next course of use of Oxaliplatinum medak is possible only after a thorough examination of the hematopoietic system. At the same time, neutrophil counts should be greater than 1500 μl and platelets more than 50,000 μl. For any violations, the appointment of the next course follows only after the restoration of the indicators. If symptoms of acute pain persist for more than a week, the next dose of Oxaliplatin medak should be reduced: for auxiliary therapy at 10 mg / m ² and for dissiminated colorectal cancer at 20 mg / m ². If sensitivity disorders persist until the next cycle, oxaliplatinum medaka is canceled.

[9], [10]

Use Oxaliplatinum medec during pregnancy

At any oncological diseases pregnancy should be interrupted. Oxaliplatinum medak can not be used by pregnant and lactating mothers. This is due to the fact that Oxaliplatinum medak is one of the strongest metabolic poisons. The ingestion of this poison into the milk of the nursing mother will be an immediate threat to the life of the baby. Often, during pregnancy and lactation, you must abandon the use of this drug. An exception may be the appointment of a doctor, but the use of oxaliplatinum medication during pregnancy is prohibited.

Contraindications

The bone marrow always reacts to the oppression of its work on radiation, chemotherapy, or therapy with biologically active agents. This reaction of the body is called myelosuppression and along with leukopenia (when the total number of peripheral blood cells decreases) is the main contraindication to the appointment of Oxalipatin medak. Also contraindicated cytostatics patients with peripheral neuropathy, which is accompanied by a violation of the sensitivity of the limbs, facial cramps, with the respiratory system and the gastrointestinal tract. Peripheral neuropathy can progress, mainly after the first course of treatment. Hypersensitivity to metabolic poison Oxalapatin medak is rare, but it does not allow the use of this cytostatic.

Side effects Oxaliplatinum medec

Chemotherapeutic use of cytotoxic Oxaliplatin medak entails a large number of adverse reactions. In the first place there are symptoms from the digestive tract, diarrhea, vomiting and other disorders can occur. Hematological disorders such as, thrombocytopenia and neutropenia are also one of the most common side effects of Oxaliplatin medak.

The frequency of side effects, which are presented here, is stated with a gradation from the most frequently observed to the very rarely observed.

The human blood system is very often the main target (after cancer cells) for metabolic poisons. This is expressed in various forms of anemia, leukopenia, neutropenia, thrombocytopenia and lymphopenia,

The digestive system also very often can not cope with the action of the cytostatic: a painful sensation in the epigastric region, vomiting, rapid defecation, damage to the oral mucosa, myositis, pain in the stomach, constipation, here is not a complete list of the possible consequences of using the chemotherapy.

The central nervous system reacts with peripheral neurosensory neuropathy, hypoesthesia, migraine and other various disorders.

[8]

Overdose

Overdose of the drug Oxaliplatinum medak, usually, leads to an increase in the number and strength of side effects. From the visible symptom it is vomiting, frequent defecation, unpleasant sensations in the epigastric region and pharynx, weakness, less often - intensification of the disorders of sensitivity and psyche of various manifestations. When overdosage with cytostatics Oxaliplatinum medak a thorough hematological control is performed, symptomatic therapy is prescribed. Substances to neutralize the effects of metabolic venom Oxaliplatin medak does not currently exist.

[11]

Interactions with other drugs

Oxaliplatin medak can not be compatible with alkaline and chlorine-containing solutions. When interacting with coagulants, the risk of bleeding increases. When interacting with non-steroidal anti-inflammatory drugs, side effects of Oxaliplatinum medak may increase. Introduced together with antimetabolites increases the cytotoxic properties of both drugs. You should tell your doctor about the medications you are using, and carefully read the annotation of these drugs.

[12]

Storage conditions

To store hermetically sealed bottles Oxaliplatinum medaka is necessary in a warm dry place at a temperature not lower than 5 ° C and not higher than 25 ° C with a relative humidity of not more than sixty percent. Be careful not to get direct sunlight on the bottles. Keep away from children and pets. It should always be remembered that oxylopathine honey is the strongest metabolic poison without an effective antidote. Shelf life after the first opening of the bottle is no more than one and a half hours.

[13], [14]

Special instructions

Oxaliplatin medak is used under the close supervision of an experienced physician. Prior to the first course and after it, hematological studies are conducted to determine the level of blood cells. Neurological examination is also performed. An antiemetic is prescribed. In the case of rapid defecation, fluid intake increases. During the reception of the chemotherapy drug Oxaliplatinum medaka should beware of contacts with sources of infection. At sexual contacts it is necessary to use measures of contraception directed first of all on protection of the partner. It is advisable to use a disposable infusion system.

Shelf life

Shelf life of the drug Oxaliplatinum medak - 4 years. Such a shelf-life of Oxaliplatin medak is possible only in cases of complete packaging and proper storage of this medication.

[15]